Daiichi Sankyo

News

Enhertu cleared for NHS use via Cancer Drugs Fund

NICE has recommended the use of AstraZeneca and Daiichi Sankyo's Enhertu in draft guidance, the first time the drug has been commissioned in any European country.

News

Daiichi Sankyo announces UK digital AF collaboration

Daiichi Sankyo has announced a collaboration with three technology partners to improve t

News

NICE backs AZ’s Calquence for new use in leukaemia

AstraZeneca’s BTK inhibitor Calquence has become the first targeted oral therapy to be backed by NICE for NHS England patients with chronic lymphocytic leukaemia (CLL) who can’t be treated

News

AZ/Daiichi Sankyo's partnership makes progress in lung cance...

AstraZeneca and Daiichi Sankyo have announced data from two drugs in lung cancer, which they are developing as part of their ongoing partnership.

News

AZ/Daiichi Sankyo's Enhertu gets second US cancer indication

AstraZeneca and Daiichi Sankyo’s Enhertu cancer drug has picked up a second indication, in patients who have stomach cancer and haven’t responded to Roche’s Herceptin (trastuzumab).

News

Radiology technician examens mammography test on location

MacroGenics' HER2 breast cancer drug Margenza approved in US

MacroGenics’ HER2-targeted breast cancer drug Margenza has been approved by the FDA, challenging several recently approved drugs with a narrow efficacy edge over Roche’s Herceptin in data g

Enhertu cleared for NHS use via Cancer Drugs Fund

Daiichi Sankyo announces UK digital AF collaboration

NICE backs AZ’s Calquence for new use in leukaemia

AZ/Daiichi Sankyo's partnership makes progress in lung cance...

AZ/Daiichi Sankyo's Enhertu gets second US cancer indication

MacroGenics' HER2 breast cancer drug Margenza approved in US

Biotech is back, with Craig Ackerman

Using AI-driven synthetic personas to take your insights fur...

Daiichi Sankyo

Editor's Picks